Table 2.
Baseline characteristics of observational dataset and PSM dataset (n = 872)
| Characteristic | Observational dataset (n = 1003) | PSM dataset (n = 872) | ||||
|---|---|---|---|---|---|---|
| PET/CT + CWU (n = 218) | CWU (n = 785) |
p | PET/CT + CWU (n = 218) | CWU (n = 654) |
p | |
| Age (yr) | 0.167 | 0.334 | ||||
| Median(range) | 44.5 (35–51) | 47 (20–81) | 44.5 (35–51) | 46 (39–54) | ||
| ≤ 45 | 119 (54.6) | 387 (49.3) | 119 (54.6) | 342 (52.3) | ||
| > 45 | 99 (45.4) | 398 (50.7) | 99 (45.4) | 312 (47.7) | ||
| Gender | 0.083 | 0.743 | ||||
| Female | 47 (21.6) | 215 (27.4) | 47 (21.6) | 148 (22.6) | ||
| Male | 171 (78.4) | 570 (72.6) | 171 (78.4) | 506 (77.4) | ||
| T stage | 0.020 | 0.810 | ||||
| T1 | 133 (61.0) | 409 (52.1) | 133 (61.0) | 393 (60.1) | ||
| T2 | 85 (39.0) | 376 (47.9) | 85 (39.0) | 261 (39.9) | ||
| N stage | 0.992 | 0.906 | ||||
| N0 | 101 (46.3) | 364 (46.4) | 101 (46.3) | 306 (46.8) | ||
| N1 | 117 (53.7) | 421 (53.6) | 117 (53.7) | 348 (53.2) | ||
| Clinical stage | 0.175 | 1.000 | ||||
| I | 74 (33.9) | 229 (29.2) | 37 (17.6) | 125 (19.8) | ||
| II | 144 (66.1) | 556 (70.8) | 173 (82.4) | 505 (80.2) | ||
| EBV DNA | 0.012 | 0.139 | ||||
| < 4000 | 168 (77.1) | 662 (84.3) | 168 (77.1) | 534 (81.7) | ||
| ≥ 4000 | 50 (22.9) | 123 (15.7) | 50 (22.9) | 120 (11.3) | ||
| Smoking | 0.722 | 0.445 | ||||
| No | 156 (71.6) | 552 (70.3) | 156 (71.6) | 450 (68.8) | ||
| Yes | 62 (28.4) | 233 (29.7) | 62 (28.4) | 204 (31.2) | ||
| Treatment | 0.568 | 0.334 | ||||
| RT | 90(55.5) | 336 (42.8) | 90 (41.3) | 288 (44.0) | ||
| CCRT | 78 (45.5) | 300 (38.2) | 78 (35.8) | 251 (38.4) | ||
| ICT + RT | 19 (8.7) | 63 (8.0) | 19 (8.7) | 49 (7.5) | ||
| ICT + CCRT | 31 (14.2) | 86 (11.0) | 31 (14.2) | 66 (10.1) | ||
p value < 0.05 indicates a statistically significant difference
Abbreviations: yr, year; EBV, Epstein–Barr virus; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; ICT, induction chemotherapy